REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
Portfolio Pulse from Vandana Singh
REGENXBIO Inc (NASDAQ:RGNX) reported positive interim safety and efficacy data from the Phase 1/2 AFFINITY DUCHENNE trial of RGX-202 for Duchenne muscular dystrophy in patients aged 4 to 11 years. The drug was well tolerated with no serious adverse events, and showed promising results in microdystrophin expression and reduction in serum creatinine kinase levels, indicating potential clinical improvement. The company plans to make a pivotal dose determination in mid-2024 and expects to initiate a pivotal trial in the second half of 2024, aiming for accelerated approval. RGNX shares surged 17.90% to $25.34.
March 05, 2024 | 5:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
REGENXBIO Inc reported positive interim results from its RGX-202 trial for Duchenne muscular dystrophy, showing no serious adverse events and signs of clinical improvement. Shares surged 17.90% to $25.34.
The positive interim safety and efficacy data from the RGX-202 trial indicate potential for clinical success and regulatory approval, which significantly boosts investor confidence and drives the stock price up. The announcement of a pivotal dose determination and the initiation of a pivotal trial in the near future further supports the positive outlook for the company and its stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100